Hem

Press release from Companies

Publicerat: 2021-10-29 10:30:18

Inhalation Sciences Sweden AB: Inhalation Sciences receives new order worth 2.9 million SEK from returning big pharma customer

(Stockholm, 29 October, 2021) Inhalation Sciences (ISAB) has signed one of the largest purchase orders in its history with a major global pharmaceutical company. The client has previously carried out two extensive clinical research projects with Inhalation Research Services (IRS). The order is for ISAB’s aerosol R&D system PreciseInhale® and its in vitro lung simulation module DissolvIt®.

The total value of the order is 299,400 KEUR (2.97 million SEK). The order follows lengthy negotiations and previous successful contract research projects for the company carried out by Inhalation Research Services.

CEO Manoush Masarrat: "This is a major milestone that validates our technology and our business model. The successful IRS research projects provided our client with such a strong technical and scientific proof of concept that the advantages of having the systems in-house - and being able to generate these kinds of results in-house - were decisive. Our technology proved itself every step of the way and we look forward to continuing our ongoing collaboration with this highly valued customer."

DissolvIt® is widely recognized as being a leading solution in the field of high-precision, predictive in vitro in vivo correlation (IVIC) data, reducing risk and identifying strong drug candidates very early in the development process – a major competitive advantage for inhaled drug developers.

For more information on Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on October 29, 1030, 2021.

Läs mer hos Cision
Läs mer om Inhalation Sciences Sweden AB

Prenumeration